Actively Recruiting
Randomized Phase 1 Trial of Glutathione Added to PD-1 Antibody and Chemotherapy in Adults with Advanced Non-Small Cell Lung Cancer
Led by The First Affiliated Hospital of Zhengzhou University · Updated on 2025-08-07
80
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether glutathione can improve the effectiveness of current chemo-immunotherapy treatments for advanced non-small cell lung cancer NSCLC. The study explores how different chemotherapy sequences affect immune cells within tumors and how glutathione may modulate the immune response to enhance treatment outcomes and patient survival. This is a phase 1 randomized controlled trial led by The First Affiliated Hospital of Zhengzhou University. Participants will receive either a combination of a PD-1 inhibitor and platinum-based doublet chemotherapy alone or the same regimen with added glutathione. The PD-1 inhibitors used include pembrolizumab, camrelizumab, sintilimab, tislelizumab, or toripalimab. Glutathione is administered as an adjunct drug to evaluate its impact on chemo-immunotherapy. The study compares these two groups to assess differences in treatment response and immune system effects. Throughout the trial, participants will be monitored for progression-free survival up to 24 months and overall response rate within 12 weeks after starting treatment. Additional assessments include immune system parameters, quality of life scores up to 24 weeks, and overall survival up to 60 months. The study involves regular evaluations to measure disease progression, immune function, and patient well-being to understand how glutathione influences treatment outcomes and safety.
CONDITIONS
Brief Title
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
Research Team
Y
Yi Zhang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here